Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Checked against the public recordLast updated Jun 14, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Nagla Abdel Karim
- Interventions being studied
- Drug: Bosutinib; Drug: Pemetrexed
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Pathologically or cytologically proven advanced, metastatic non-squamous non-small cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical cancer. * Measurable disease * Life expectancy of greater than 3 months. * Ability to take folic acid, vitamin B12, and dexamethasone according to protocol. Exclusion Criteria: \- Untreated or symptomatic brain metastases.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Augusta University Georgia Cancer CenterAugusta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 14, 2022. Always confirm current availability with the study team.